Drug Profile
Research programme: antibody and protein-based therapeutics - Ambrx/Eli Lilly and Company
Latest Information Update: 13 Mar 2024
Price :
$50
*
At a glance
- Originator Ambrx; Eli Lilly and Company
- Class Antibodies; Proteins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported CNS disorders; Metabolic disorders